IMD business school for management and leadership courses

Many companies overestimate customers’ appetite for sustainable products, flooding the market with offerings that don’t sell. The reality is, social and environmental benefits have less impact on purchasing decisions than basic product attributes do. Consumers buy products to get specific jobs done, and only after they find something that will d…

The AI boom — and the growth of gen AI in particular — has introduced new points of conflict between employees and companies. Some of these have already started to play out, such as in the Writers Guild of America strike over how AI can and can’t be used in the entertainment industry. But others are still on the horizon. As AI becomes more integ…

Corporate transformations still have a miserable success rate: About three-quarters of change efforts either fail to deliver the anticipated benefits or are abandoned entirely. And because flawed implementation is most often blamed for such failures, organizations have focused on improving execution. But poor execution is only part of the proble…

Harald (not his real name) is a highpotential leader with 15 years of experience at a leading European chemical company. He started as an assistant product manager in the plastics unit and was quickly transferred to Hong Kong to help set up the unit’s new Asian business center. As sales there soared, he soon won a promotion to sales manager. Thr…

France’s recent successes make it more important than ever to understand what makes its managers tick. This year, France surpassed Japan and the U.K. in acquisitions of U.S. companies. And many French companies are world leaders, including Michelin and L’Oreal. According to the authors, who have studied the French model of management development…

Eight years ago, Malnight, Buche, and Dhanaraj launched a study of high growth in companies, looking at three strategies known to drive it: creating new markets, serving broader stakeholder needs, and rewriting the rules of the game. To their surprise, they discovered a fourth driver they hadn’t considered at all: purpose. Companies have long be…

Chugai C focuses on the company’s future as it celebrates its 100th anniversary in 2025. In 2021, Chugai launched its ambitious ‘TOP I 2030’ growth strategy, aiming to transition from Japan’s top innovator to a global leader. The strategy sets two primary targets: doubling RD output and launching one in-house global product annually by 2030. The…

Chugai B examines the pivotal strategic alliance formed in October 2002 between Chugai Pharmaceutical and Swiss giant Roche. Facing constraints in RD funding and global reach, Chugai’s President Osamu Nagayama sought a partnership to achieve the firm’s ambition of becoming Japan’s number one pharmaceutical enterprise while preserving its autonom…

Chugai A traces the transformative journey of a leading Japanese biopharmaceutical firm from its founding in 1925 to the early 2000s. Starting with founder Jz Ueno’s vision to ‘create medicines that benefit society,’ the case details the company’s evolution from an over-the-counter OTC drug importer to a research-driven enterprise. Key milestone…

This Technical Note presents a comprehensive framework of ten evidence-based principles for improving decision-making effectiveness in leadership contexts. Drawing from cognitive science, behavioral economics and management theory, it addresses the critical challenge that leaders face in making sound decisions under pressure and uncertainty.The …

The case follows Kristin Hull, founder and CIO of Nia Impact Capital, a mission-driven investment firm in California, as she faces a pivotal decision in July 2025: Should she file a shareholder resolution against Tesla, Inc.? Hull and Nia have engaged Tesla for over five years on issues of human capital management, workplace equity and board ove…

The case looks at the fundamental challenges, tensions and opportunities associated with an internally run venture as opposed to an externally funded startup or spin-off company. It discusses the genesis and context of Kontor, an internal venture funded by Resmed Inc. Resmed is an S&P 500 MedTech company. At the time of the case, May 2024, Konto…

Aging is being reframed as a biological process that can be measured and potentially altered. The longevity market is evolving fast and cannot be ignored.

A skills-powered approach to talent management can boost agility, efficiency, and productivity, but transitioning to it is a complex undertaking.

Former Novo Nordisk CSO Marcus Schindler on R&D leadership, pharma innovation, scientific discovery, AI, global talent, DEI, biotech, drug development strategy.

CEO Dialogue SeriesPlay VideoCreating a smokeless zone: How PMI is stubbing out cigarettes2 weeks ago in CEO Dialogue SeriesCEO Dialogue Series Play Video Creating a smokeless zone: How PMI is stubbing out cigarettes 2 weeks ago in CEO Dialogue Series DownloadSave Christophe Fouquet, CEO of ASML, tells Jean-François Manzoni how…DownloadSave te…

Discover five strategic imperatives to turn geopolitical uncertainty into a competitive advantage and build lasting business resilience beyond crisis management.

AI and sustainability are transforming the business landscape, yet many organizations treat the two as separate mandates. Instead, they must integrate these forces.